{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:42:30Z","timestamp":1785393750591,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40272-016-0206-0","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T02:36:26Z","timestamp":1484102186000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pediatric Development of Bosentan Facilitated by Modeling and Simulation"],"prefix":"10.1007","volume":"19","author":[{"given":"Jochen","family":"Zisowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"G\u00e9hin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andjela","family":"Kusic-Pajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Beghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"issue":"134","key":"206_CR1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1183\/09059180.00007614","volume":"23","author":"V McLaughlin","year":"2014","unstructured":"McLaughlin V, Simonneau G, Galie N, Rubin LJ. New horizons in pulmonary arterial hypertension management. Eur Respir Rev. 2014;23(134):408\u20139.","journal-title":"Eur Respir Rev"},{"issue":"18","key":"206_CR2","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.jacc.2015.03.540","volume":"65","author":"VV McLaughlin","year":"2015","unstructured":"McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976\u201397.","journal-title":"J Am Coll Cardiol"},{"issue":"25 Suppl","key":"206_CR3","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","volume":"62","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"206_CR4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1183\/09031936.00056110","volume":"37","author":"RJ Barst","year":"2011","unstructured":"Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J. 2011;37(3):665\u201377.","journal-title":"Eur Respir J"},{"issue":"2","key":"206_CR5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/157016109787455653","volume":"7","author":"M Beghetti","year":"2009","unstructured":"Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol. 2009;7(2):225\u201333.","journal-title":"Curr Vasc Pharmacol"},{"issue":"9","key":"206_CR6","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2010.06.064","volume":"106","author":"DD Ivy","year":"2010","unstructured":"Ivy DD, Rosenzweig EB, Lemari\u00e9 J-C, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol. 2010;106(9):1332\u20138.","journal-title":"Am J Cardiol."},{"key":"206_CR7","unstructured":"European Medicines Agency. Tracleer in pulmonary arterial hypertension: summary of product characteristics. 2012 [cited Jan 22, 2016]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000401\/WC500041597.pdf ."},{"key":"206_CR8","unstructured":"U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Prescribing information: Tracleer (bosentan) tablets, for oral use. 2001-2015 [cited 2016 Jan 22, 2016]. Available from: https:\/\/www.tracleerrems.com\/docs\/Tracleer_Full_Prescribing_Information.pdf , http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021290s012lbl.pdf ."},{"issue":"4","key":"206_CR9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","volume":"73","author":"RJ Barst","year":"2003","unstructured":"Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73(4):372\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"206_CR10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2125.2009.03532.x","volume":"68","author":"M Beghetti","year":"2009","unstructured":"Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol. 2009;68(6):948\u201355.","journal-title":"Br J Clin Pharmacol"},{"key":"206_CR11","unstructured":"European Medicines Agency. Tracleer (bosentan): summary of the European public assessment report. 2009 March 13, 2015 [cited 2016 Jan 22, 2016]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000401\/human_med_001100.jsp ."},{"issue":"25 Suppl","key":"206_CR12","doi-asserted-by":"crossref","first-page":"D117","DOI":"10.1016\/j.jacc.2013.10.028","volume":"62","author":"DD Ivy","year":"2013","unstructured":"Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D117\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"206_CR13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpeds.2016.06.078","volume":"177","author":"RH Steinhorn","year":"2016","unstructured":"Steinhorn RH, Fineman J, Kusic-Pajic A, Cornelisse P, Gehin M, Nowbakht P, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the multicenter placebo-controlled FUTURE-4 trial. J Pediatr. 2016;177:90\u20136.","journal-title":"J Pediatr"},{"issue":"Suppl 2","key":"206_CR14","first-page":"A13503","volume":"130","author":"RH Steinhorn","year":"2014","unstructured":"Steinhorn RH, Kusic-Pajic A, Cornelisse P, Fineman JR, Gehin M, Nowbakht P, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the FUTURE-4 study. Circulation. 2014;130(Suppl 2):A13503.","journal-title":"Circulation"},{"key":"206_CR15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fphys.2011.00004","volume":"2","author":"T Eissing","year":"2011","unstructured":"Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, et al. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol. 2011;2:4.","journal-title":"Front Physiol."},{"issue":"15","key":"206_CR16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","volume":"43","author":"J Dingemanse","year":"2004","unstructured":"Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43(15):1089\u2013115.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"206_CR17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","volume":"35","author":"A Treiber","year":"2007","unstructured":"Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35(8):1400\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"206_CR18","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","volume":"45","author":"AN Edginton","year":"2006","unstructured":"Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013\u201334.","journal-title":"Clin Pharmacokinet"},{"key":"206_CR19","unstructured":"Lixoft-Incuballiance. Monolix User Guide. 4.2.0 ed. Orsay, France; 2012."},{"issue":"134","key":"206_CR20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1183\/09059180.00007714","volume":"23","author":"M Beghetti","year":"2014","unstructured":"Beghetti M, Berger RM. The challenges in paediatric pulmonary arterial hypertension. Eur Respir Rev. 2014;23(134):498\u2013504.","journal-title":"Eur Respir Rev"},{"key":"206_CR21","unstructured":"U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). New drug application #203109: sildenafil. Clinical review. 2012 [cited 2016 Feb 16, 2016]. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM320472.pdf ."},{"key":"206_CR22","unstructured":"U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). New drug application #203109: sildenafil. Summary review. 2012 [cited 2016 Feb 16, 2016]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203109Orig1s000SumR.pdf ."},{"issue":"25 Suppl","key":"206_CR23","doi-asserted-by":"crossref","first-page":"D82","DOI":"10.1016\/j.jacc.2013.10.026","volume":"62","author":"M Gomberg-Maitland","year":"2013","unstructured":"Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, et al. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D82\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"206_CR24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1183\/09031936.00140112","volume":"42","author":"M Beghetti","year":"2013","unstructured":"Beghetti M, Berger RM, Schulze-Neick I, Day RW, Pulido T, Feinstein J, et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J. 2013;42(3):689\u2013700.","journal-title":"Eur Respir J."},{"issue":"203","key":"206_CR25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijcard.2015.10.087","volume":"15","author":"M Beghetti","year":"2016","unstructured":"Beghetti M, Schulze-Neick I, Berger RM, Ivy DD, Bonnet D, Weintraub RG, et al. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). Int J Cardiol. 2016;15(203):325\u201330.","journal-title":"Int J Cardiol"},{"issue":"5","key":"206_CR26","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","volume":"128","author":"J Dunne","year":"2011","unstructured":"Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart GJ, Filie JD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011;128(5):e1242\u20139.","journal-title":"Pediatrics"},{"issue":"7","key":"206_CR27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jcph.488","volume":"55","author":"F Foissac","year":"2015","unstructured":"Foissac F, Bouazza N, Valade E, De Sousa Mendes M, Fauchet F, Benaboud S, et al. Prediction of drug clearance in children. J Clin Pharmacol. 2015;55(7):739\u201347.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"206_CR28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"206_CR29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40262-015-0298-7","volume":"54","author":"F Rodieux","year":"2015","unstructured":"Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clin Pharmacokinet. 2015;54(12):1183\u2013204.","journal-title":"Clin Pharmacokinet"},{"key":"206_CR30","doi-asserted-by":"crossref","unstructured":"Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT. 2013;2:e63.","DOI":"10.1038\/psp.2013.41"},{"issue":"2","key":"206_CR31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1208\/s12248-012-9446-2","volume":"15","author":"HM Jones","year":"2013","unstructured":"Jones HM, Mayawala K, Poulin P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J. 2013;15(2):377\u201387.","journal-title":"AAPS J"},{"key":"206_CR32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fphar.2014.00258","volume":"5","author":"M Chetty","year":"2014","unstructured":"Chetty M, Rose RH, Abduljalil K, Patel N, Lu G, Cain T, et al. Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Front Pharmacol. 2014;5:258.","journal-title":"Front Pharmacol."},{"issue":"2","key":"206_CR33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","volume":"39","author":"EJ Guest","year":"2011","unstructured":"Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011;39(2):170\u20133.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"206_CR34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/138920008786485164","volume":"9","author":"JB Houston","year":"2008","unstructured":"Houston JB, Galetin A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab. 2008;9(9):940\u201351.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"206_CR35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/dmd.110.032177","volume":"38","author":"YH Wang","year":"2010","unstructured":"Wang YH. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos. 2010;38(7):1094\u2013104.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"206_CR36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0009-9236(96)90127-7","volume":"60","author":"C Weber","year":"1996","unstructured":"Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996;60(2):124\u201337.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"206_CR37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/00912700222011300","volume":"42","author":"J Dingemanse","year":"2002","unstructured":"Dingemanse J, Bodin F, Weidekamm E, Kutz K, van Giersbergen P. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol. 2002;42(3):283\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"206_CR38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/00912709922008344","volume":"39","author":"C Weber","year":"1999","unstructured":"Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol. 1999;39(7):703\u201314.","journal-title":"J Clin Pharmacol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0206-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-016-0206-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0206-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:54:54Z","timestamp":1498362894000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-016-0206-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s40272-016-0206-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]}}}